Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia

BACKGROUND: Ustekinumab was approved in 2016 for the treatment of moderate–severe Crohn’s disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Inniss, Saskia, Fragkos, Konstantinos C., Whitley, Lisa, Wimpory, Rachel, Rebello, Eleanor, Lisboa, Ana, Khetan, Tanvi, Hassan, Jasmine, Simpson, Kate, Bhagwanani, Anisha, Vega, Roser, Parisi, Ioanna, Harrow, Paul, Seward, Edward, McCartney, Sara, Bloom, Stuart, Smith, Andrew M., Plumb, Andrew, Rahman, Farooq Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434845/
https://www.ncbi.nlm.nih.gov/pubmed/37601038
http://dx.doi.org/10.1177/20406223231189072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434845/
https://www.ncbi.nlm.nih.gov/pubmed/37601038
http://dx.doi.org/10.1177/20406223231189072

Ejemplares similares